Literature DB >> 11106495

Engineered eglin c variants inhibit yeast and human proprotein processing proteases, Kex2 and furin.

T Komiyama1, R S Fuller.   

Abstract

We engineered eglin c, a potent subtilisin inhibitor, to create inhibitors for enzymes of the Kex2/furin family of proprotein processing proteases. A structural gene was synthesized that encoded "R(1)-eglin", having Arg at P(1) in the reactive site loop in place of Leu(45). Ten additional variants were created by cassette mutagenesis of R(1)-eglin. These polypeptides were expressed in Escherichia coli, purified to homogeneity, and their interactions with secreted, soluble Kex2 and furin were examined. R(1)-eglin itself was a modest inhibitor of Kex2, with a K(a) of approximately 10(7) M(-)(1). Substituting Arg (in R(4)R(1)-eglin) or Met (in M(4)R(1)-eglin) for Pro(42) at P(4) created potent Kex2 inhibitors exhibiting K(a) values of approximately 10(9) M(-)(1). R(4)R(1)-eglin inhibited furin with a K(a) of 4.0 x 10(8) M(-)(1). Introduction of Lys at P(1), in place of Arg in R(4)R(1)-eglin reduced affinity only approximately 3-fold for Kex2 but 15-fold for furin. The stabilities of enzyme-inhibitor complexes were characterized by association and dissociation rate constants and visualized by polyacrylamide gel electrophoresis. R(4)R(1)-eglin formed stable 1:1 complexes with both Kex2 and furin. However, substitution of Lys at P(2) in place of Thr(44) resulted in eglin variants that inhibited both Kex2 and furin but which were eventually cleaved (temporary inhibition). Surprisingly, R(6)R(4)R(1)-eglin, in which Arg was substituted for Gly(40) in R(4)R(1)-eglin, exhibited stable, high-affinity complex formation with Kex2 (K(a) of 3.5 x 10(9) M(-)(1)) but temporary inhibition of furin. This suggests that enzyme-specific interactions can alter the conformation of the reactive site loop, converting a permanent inhibitor into a substrate. Eglin variants offer possible avenues for affinity purification, crystallization, and regulation of proprotein processing proteases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106495     DOI: 10.1021/bi001907c

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  19 in total

Review 1.  Furin at the cutting edge: from protein traffic to embryogenesis and disease.

Authors:  Gary Thomas
Journal:  Nat Rev Mol Cell Biol       Date:  2002-10       Impact factor: 94.444

2.  A clogged gutter mechanism for protease inhibitors.

Authors:  Evette S Radisky; Daniel E Koshland
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-25       Impact factor: 11.205

3.  Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases.

Authors:  Gero L Becker; Yinghui Lu; Kornelia Hardes; Boris Strehlow; Christine Levesque; Iris Lindberg; Kirsten Sandvig; Udo Bakowsky; Robert Day; Wolfgang Garten; Torsten Steinmetzer
Journal:  J Biol Chem       Date:  2012-04-26       Impact factor: 5.157

4.  Identification of serpin determinants of specificity and selectivity for furin inhibition through studies of α1PDX (α1-protease inhibitor Portland)-serpin B8 and furin active-site loop chimeras.

Authors:  Gonzalo Izaguirre; Lixin Qi; Mary Lima; Steven T Olson
Journal:  J Biol Chem       Date:  2013-06-06       Impact factor: 5.157

5.  Long-range electrostatic complementarity governs substrate recognition by human chymotrypsin C, a key regulator of digestive enzyme activation.

Authors:  Jyotica Batra; András Szabó; Thomas R Caulfield; Alexei S Soares; Miklós Sahin-Tóth; Evette S Radisky
Journal:  J Biol Chem       Date:  2013-02-19       Impact factor: 5.157

6.  Overlapping Specificity of Duplicated Human Pancreatic Elastase 3 Isoforms and Archetypal Porcine Elastase 1 Provides Clues to Evolution of Digestive Enzymes.

Authors:  Eszter Boros; András Szabó; Katalin Zboray; Dávid Héja; Gábor Pál; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2017-01-06       Impact factor: 5.157

7.  Stability of mutant serpin/furin complexes: dependence on pH and regulation at the deacylation step.

Authors:  Erick K Dufour; Antoine Désilets; Jean-Michel Longpré; Richard Leduc
Journal:  Protein Sci       Date:  2005-02       Impact factor: 6.725

8.  Specific and Selective Inhibitors of Proprotein Convertases Engineered by Transferring Serpin B8 Reactive-Site and Exosite Determinants of Reactivity to the Serpin α1PDX.

Authors:  Gonzalo Izaguirre; Marcelino Arciniega; Andrea G Quezada
Journal:  Biochemistry       Date:  2019-03-08       Impact factor: 3.162

Review 9.  Inhibitors of proprotein convertases.

Authors:  Ajoy Basak
Journal:  J Mol Med (Berl)       Date:  2005-10-08       Impact factor: 4.599

10.  Synthetic small-molecule prohormone convertase 2 inhibitors.

Authors:  Dorota Kowalska; Jin Liu; Jon R Appel; Akihiko Ozawa; Adel Nefzi; Robert B Mackin; Richard A Houghten; Iris Lindberg
Journal:  Mol Pharmacol       Date:  2008-12-12       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.